Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Truist Financial Sticks to Their Buy Rating for Viridian Therapeutics (VRDN)

Tipranks - Tipranks - Sat Feb 28, 7:00AM CST

In a report released today, Gregory Renza from Truist Financial maintained a Buy rating on Viridian Therapeutics, with a price target of $40.00.

Claim 50% Off TipRanks Premium

According to TipRanks, Renza is a 5-star analyst with an average return of 20.2% and a 50.42% success rate. Renza covers the Healthcare sector, focusing on stocks such as Gilead Sciences, Fulcrum Therapeutics, and Viridian Therapeutics.

In addition to Truist Financial, Viridian Therapeutics also received a Buy from RBC Capital’s Lisa Walter in a report issued today. However, on the same day, TipRanks – Anthropic reiterated a Hold rating on Viridian Therapeutics (NASDAQ: VRDN).

See the top stocks recommended by analysts >>

Based on Viridian Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $132 thousand and a GAAP net loss of $120.36 million. In comparison, last year the company earned a revenue of $72 thousand and had a GAAP net loss of $79.73 million

Read More on VRDN:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).